ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Chemotherapy

May 26, 2022
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
January 27, 2021
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
November 21, 2020
A scholarly and sober narrative review on , as the authors state,  a ' hot topic' that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
November 7, 2019
This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with advanced lung cancer.
April 17, 2019
Dr Burt gives a brief overview of the considerable advances for patients with thoracic malignancies (non–small cell lung cancer in particular).
October 23, 2018
Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard maintenance therapy.  Overall survival for the intervention group was 41.2 mos vs 17.0 mos in those getting maintenance therapy (p=0.017). 
October 11, 2018
This analysis of the National Cancer Database included over 2000 eligible patients resected with N2 disease who did not receive induction therapy. The addition of radiotherapy to postoperative chemotherapy did not affect survival in either the unmatched or the matched groups. 
September 25, 2018
This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival.  Tumor mutational burden was a marker for patient selection for immunotherapy.

Pages